Displaying drugs 11826 - 11850 of 12280 in total
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
Matched Description: … an altered peptide ligand that is designed to cause an immune response which result in preservation of …
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. ... It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile. …
Cythioate
Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.
Vet approved
Matched Description: … Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic ... It is mainly used in veterinary as a treatment for fleas. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Emibetuzumab
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Investigational
Matched Description: … Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, …
Lumretuzumab
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Investigational
Matched Description: … Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small …
Milatuzumab
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), …
Rovalpituzumab tesirine
Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Investigational
Matched Description: … Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma …
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
Matched Description: … GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal …
BMS-986141
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
Investigational
Matched Description: … of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants). ... BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics …
JNJ-42165279
Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Investigational
Matched Description: … 42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of …
Lisavanbulin
Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Investigational
Matched Description: … Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48 …
SAR-125844
SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).
Investigational
Matched Description: … SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered …
V116517
V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
Investigational
Matched Description: … V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 …
CR6086
CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).
Investigational
Matched Description: … CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in …
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Description: … It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] ... MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. …
Elacytarabine
Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. Elacytarabine is a patented...
Investigational
Matched Description: … Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. ... Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological …
KBP-COVID-19
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As...
Investigational
Matched Description: … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity ... of KBP-COVID-19 vaccine in healthy patients (NCT04473690). ... KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco …
IL15-NK Cell
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Displaying drugs 11826 - 11850 of 12280 in total